Cargando...
Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo
BACKGROUND: Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and chemotherapy recurrence is inevitable. A stem-like population of radio- and chemoresista...
Gardado en:
| Publicado en: | BMC Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5341392/ https://ncbi.nlm.nih.gov/pubmed/28270132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3162-3 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|